Inspire Medical Systems (2DR) AI Stock Analysis
Inspire Medical Systems
(Frankfurt:2DR)
No summary available
Inspire Medical Systems (2DR) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.97B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- 14.6
- Beta (1Y)
- 0.63
- Revenue Growth
- -2.76%
- EPS Growth
- 141.27%
- Country
- Germany
- Employees
- 1,333
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Inspire Medical Systems Business Overview & Revenue Model
Company Description
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domesti...
Inspire Medical Systems Earnings Call Summary
The call presented a balanced picture: meaningful near-term headwinds from coding and reimbursement disruption depressed top-line growth (Q2 revenue down 7.6% and a full-year disruption impact estimated at $120M–$130M), drove elevated tax and restructuring items, and widened near-term guidance. Offsetting these challenges, management delivered profitability and positive operating cash flow ahead of expectations, possesses a strong cash position ($415M, no debt), announced Project Horizon to create $30M of reinvestment capacity, and highlighted strong clinical evidence and favorable proposed CMS facility reimbursement changes (+12% hospital, +15% ASC for 2027). Given the comparable weight of material negatives (revenue/headwinds, restructuring, reimbursement uncertainty) and material positives (cashflow, balance sheet, clinical momentum and planned reinvestment), the overall tone is balanced with a path to recovery but meaningful near-term uncertainty.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management updated 2026 guidance, raising full‑year revenue to $835–$875 million while estimating a total adverse impact from coding/reimbursement and WISeR of $120–$130 million for the year (about $40 million in Q2); they expect Q3 revenue to be down 8–10% year‑over‑year with roughly breakeven adjusted operating income. For the year they target adjusted operating margin of 4–6%, GAAP diluted EPS of a loss of $0.42 to earnings of $0.17, adjusted diluted EPS of $1.05–$1.45, an effective tax rate of 95–100% (adjusted tax rate 30–35%), weighted average diluted shares of ~29.4 million, and capital expenditures of $35–$40 million. They expect to take Project Horizon pretax restructuring charges of $20–$25 million (≈90% in Q3), including $16–$20 million of noncash impairments, to create about $30 million of annualized growth investment capacity. Q2 actuals cited on the call included revenue of $200.6 million (−7.6% YoY), operating cash flow of $23.2 million (YTD $36.1M), cash & investments of $415 million, Q2 diluted EPS $0.01 (adjusted $0.14) and adjusted EBITDA margin of 19.4%.
Inspire Medical Systems Risk Analysis
Inspire Medical Systems disclosed 61 risk factors in its most recent earnings report. Inspire Medical Systems reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskInspire Medical Systems Peers Comparison
Overall Rating
RMD81Outperform
MDT74Outperform
ABT69Neutral
LIVN69Neutral
NPCE44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| RMD | 81Outperform | $32.34B | 20.92 | 25.14% | 1.07% | 9.04% | 12.22% |
| MDT | 74Outperform | $123.49B | 23.60 | 10.60% | 2.96% | 9.77% | 12.28% |
| ABT | 69Neutral | $183.77B | 39.33 | 9.12% | 2.37% | 10.00% | ― |
| LIVN | 69Neutral | $4.35B | 22.89 | 15.41% | ― | 12.39% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NPCE | 44Neutral | $422.19M | -21.51 | -119.68% | ― | 11.59% | 31.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:2DR | Inspire Medical | 61.50 | -0.32 | -0.52% | |
| ABT | Abbott Laboratories | 106.20 | -14.64 | -12.11% | |
| MDT | Medtronic | 96.54 | 9.23 | 10.58% | |
| RMD | Resmed Inc | 229.94 | -16.40 | -6.66% | |
| LIVN | LivaNova PLC | 78.97 | 26.39 | 50.19% | |
| NPCE | Neuropace, Inc. | 12.30 | 2.90 | 30.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.